Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation
NCT02634827 · Mayo Clinic · PHASE2 · terminated · last registry update 2019-08-07 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Mayo Clinic |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FLT3 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-07-07Results posted on the registry: National Cancer Institute (NCI), Asparaginase + Bortezomib (NCT01371981)
- 2020-03-03Phase 3 first posted: Children's Oncology Group, Asparaginase Erwinia chrysanthemi + Cytarabine (NCT04293562)
- 2019-10-17Results posted on the registry: Astellas Pharma Global Development, Inc., gilteritinib + LoDAC (Low Dose Cytarabine) (NCT02421939)
- 2019-07-19Phase 3 first posted: Stichting Hemato-Oncologie voor Volwassenen Nederland, Gilteritinib + Midostaurin (NCT04027309)
- 2019-02-20Results posted on the registry: Astellas Pharma Global Development, Inc., Gilteritinib + Voriconazole (NCT02014558)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision